Assenagon Asset Management S.A. Buys 19,741 Shares of IDEXX Laboratories, Inc. $IDXX

Assenagon Asset Management S.A. boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 35.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 75,609 shares of the company’s stock after buying an additional 19,741 shares during the quarter. Assenagon Asset Management S.A.’s holdings in IDEXX Laboratories were worth $51,152,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth about $26,000. Park Place Capital Corp bought a new position in IDEXX Laboratories during the 4th quarter valued at about $29,000. WealthCollab LLC bought a new position in IDEXX Laboratories during the 2nd quarter valued at about $30,000. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories in the 3rd quarter worth about $31,000. Finally, Armstrong Advisory Group Inc. raised its position in IDEXX Laboratories by 55.9% in the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. BTIG Research dropped their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Barclays reduced their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. Piper Sandler dropped their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, January 29th. Seven research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $783.33.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total value of $1,781,527.22. Following the transaction, the executive vice president owned 19,899 shares of the company’s stock, valued at $13,163,984.46. The trade was a 11.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the transaction, the executive vice president owned 9,823 shares of the company’s stock, valued at approximately $6,352,730.56. This trade represents a 53.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last three months. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Down 1.4%

Shares of NASDAQ IDXX opened at $570.21 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The stock’s fifty day simple moving average is $639.93 and its two-hundred day simple moving average is $663.76. The stock has a market capitalization of $45.34 billion, a PE ratio of 43.63, a price-to-earnings-growth ratio of 3.51 and a beta of 1.66. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.